52
Gaetano Di Chiara Gaetano Di Chiara University of Cagliari University of Cagliari Department Department of of Toxicology Toxicology , , Centre for Studies Centre for Studies on on Dependence Dependence ,MIUR and CNR ,MIUR and CNR Institute Institute of of Neuroscience Neuroscience Verona, Verona, June June 2006 2006 Neurobiology Neurobiology of of vulnerability to drug dependence vulnerability to drug dependence . .

Neurobiology of vulnerability to drug dependence. Gaetano Di Chiara · 2016. 11. 7. · Wayne C. Drevets, M.D., Julie C. Price, Ph.D., David J. Kupfer, M.D., Paul E. Kinahan, P Brian

  • Upload
    others

  • View
    1

  • Download
    0

Embed Size (px)

Citation preview

Page 1: Neurobiology of vulnerability to drug dependence. Gaetano Di Chiara · 2016. 11. 7. · Wayne C. Drevets, M.D., Julie C. Price, Ph.D., David J. Kupfer, M.D., Paul E. Kinahan, P Brian

Gaetano Di Chiara Gaetano Di Chiara

University of Cagliari University of Cagliari –– Department Department of of ToxicologyToxicology,,Centre for Studies Centre for Studies on on DependenceDependence,MIUR and CNR ,MIUR and CNR Institute Institute of of NeuroscienceNeuroscience

Verona, Verona, JuneJune 20062006

Neurobiology Neurobiology of of vulnerability to drug dependencevulnerability to drug dependence. .

Page 2: Neurobiology of vulnerability to drug dependence. Gaetano Di Chiara · 2016. 11. 7. · Wayne C. Drevets, M.D., Julie C. Price, Ph.D., David J. Kupfer, M.D., Paul E. Kinahan, P Brian
Page 3: Neurobiology of vulnerability to drug dependence. Gaetano Di Chiara · 2016. 11. 7. · Wayne C. Drevets, M.D., Julie C. Price, Ph.D., David J. Kupfer, M.D., Paul E. Kinahan, P Brian
Page 4: Neurobiology of vulnerability to drug dependence. Gaetano Di Chiara · 2016. 11. 7. · Wayne C. Drevets, M.D., Julie C. Price, Ph.D., David J. Kupfer, M.D., Paul E. Kinahan, P Brian
Page 5: Neurobiology of vulnerability to drug dependence. Gaetano Di Chiara · 2016. 11. 7. · Wayne C. Drevets, M.D., Julie C. Price, Ph.D., David J. Kupfer, M.D., Paul E. Kinahan, P Brian
Page 6: Neurobiology of vulnerability to drug dependence. Gaetano Di Chiara · 2016. 11. 7. · Wayne C. Drevets, M.D., Julie C. Price, Ph.D., David J. Kupfer, M.D., Paul E. Kinahan, P Brian
Page 7: Neurobiology of vulnerability to drug dependence. Gaetano Di Chiara · 2016. 11. 7. · Wayne C. Drevets, M.D., Julie C. Price, Ph.D., David J. Kupfer, M.D., Paul E. Kinahan, P Brian
Page 8: Neurobiology of vulnerability to drug dependence. Gaetano Di Chiara · 2016. 11. 7. · Wayne C. Drevets, M.D., Julie C. Price, Ph.D., David J. Kupfer, M.D., Paul E. Kinahan, P Brian
Page 9: Neurobiology of vulnerability to drug dependence. Gaetano Di Chiara · 2016. 11. 7. · Wayne C. Drevets, M.D., Julie C. Price, Ph.D., David J. Kupfer, M.D., Paul E. Kinahan, P Brian
Page 10: Neurobiology of vulnerability to drug dependence. Gaetano Di Chiara · 2016. 11. 7. · Wayne C. Drevets, M.D., Julie C. Price, Ph.D., David J. Kupfer, M.D., Paul E. Kinahan, P Brian
Page 11: Neurobiology of vulnerability to drug dependence. Gaetano Di Chiara · 2016. 11. 7. · Wayne C. Drevets, M.D., Julie C. Price, Ph.D., David J. Kupfer, M.D., Paul E. Kinahan, P Brian
Page 12: Neurobiology of vulnerability to drug dependence. Gaetano Di Chiara · 2016. 11. 7. · Wayne C. Drevets, M.D., Julie C. Price, Ph.D., David J. Kupfer, M.D., Paul E. Kinahan, P Brian
Page 13: Neurobiology of vulnerability to drug dependence. Gaetano Di Chiara · 2016. 11. 7. · Wayne C. Drevets, M.D., Julie C. Price, Ph.D., David J. Kupfer, M.D., Paul E. Kinahan, P Brian
Page 14: Neurobiology of vulnerability to drug dependence. Gaetano Di Chiara · 2016. 11. 7. · Wayne C. Drevets, M.D., Julie C. Price, Ph.D., David J. Kupfer, M.D., Paul E. Kinahan, P Brian
Page 15: Neurobiology of vulnerability to drug dependence. Gaetano Di Chiara · 2016. 11. 7. · Wayne C. Drevets, M.D., Julie C. Price, Ph.D., David J. Kupfer, M.D., Paul E. Kinahan, P Brian
Page 16: Neurobiology of vulnerability to drug dependence. Gaetano Di Chiara · 2016. 11. 7. · Wayne C. Drevets, M.D., Julie C. Price, Ph.D., David J. Kupfer, M.D., Paul E. Kinahan, P Brian
Page 17: Neurobiology of vulnerability to drug dependence. Gaetano Di Chiara · 2016. 11. 7. · Wayne C. Drevets, M.D., Julie C. Price, Ph.D., David J. Kupfer, M.D., Paul E. Kinahan, P Brian
Page 18: Neurobiology of vulnerability to drug dependence. Gaetano Di Chiara · 2016. 11. 7. · Wayne C. Drevets, M.D., Julie C. Price, Ph.D., David J. Kupfer, M.D., Paul E. Kinahan, P Brian

University of Cagliari University of Cagliari -- Department of Toxicology and CNR Department of Toxicology and CNR -- Center for NeuropharmacologyCenter for Neuropharmacology

Page 19: Neurobiology of vulnerability to drug dependence. Gaetano Di Chiara · 2016. 11. 7. · Wayne C. Drevets, M.D., Julie C. Price, Ph.D., David J. Kupfer, M.D., Paul E. Kinahan, P Brian
Page 20: Neurobiology of vulnerability to drug dependence. Gaetano Di Chiara · 2016. 11. 7. · Wayne C. Drevets, M.D., Julie C. Price, Ph.D., David J. Kupfer, M.D., Paul E. Kinahan, P Brian

W.C. Drevets, C. Gautier, J.C. Price, D.J. Kupfer, P.E. Kinahan, A.A. Grace,J.L. Price, and C.A. Mathis Amphetamine-Induced Dopamine Release in Human Ventral Striatum Correlates with EuphoriaBiol. Psychiatry 2001;49:81–96

Page 21: Neurobiology of vulnerability to drug dependence. Gaetano Di Chiara · 2016. 11. 7. · Wayne C. Drevets, M.D., Julie C. Price, Ph.D., David J. Kupfer, M.D., Paul E. Kinahan, P Brian

Wayne C. Drevets, M.D., Julie C. Price, Ph.D., David J. Kupfer, M.D., Paul E. Kinahan, PBrian Lopresti, B.S., Daniel Holt, B.S., and Chester Mathis, Ph.DPET Measures of Amphetamine-Induced Dopamine Releasein Ventral versus Dorsal StriatumNEUROPSYCHOPHARMACOLOGY 1999–VOL. 21, NO. 6

Page 22: Neurobiology of vulnerability to drug dependence. Gaetano Di Chiara · 2016. 11. 7. · Wayne C. Drevets, M.D., Julie C. Price, Ph.D., David J. Kupfer, M.D., Paul E. Kinahan, P Brian

W.C. Drevets, C. Gautier, J.C. Price, D.J. Kupfer, P.E. Kinahan, A.A. Grace,J.L. Price, and C.A. Mathis Amphetamine-Induced Dopamine Release in Human Ventral Striatum Correlates with EuphoriaBiol. Psychiatry 2001;49:81–96

Page 23: Neurobiology of vulnerability to drug dependence. Gaetano Di Chiara · 2016. 11. 7. · Wayne C. Drevets, M.D., Julie C. Price, Ph.D., David J. Kupfer, M.D., Paul E. Kinahan, P Brian
Page 24: Neurobiology of vulnerability to drug dependence. Gaetano Di Chiara · 2016. 11. 7. · Wayne C. Drevets, M.D., Julie C. Price, Ph.D., David J. Kupfer, M.D., Paul E. Kinahan, P Brian
Page 25: Neurobiology of vulnerability to drug dependence. Gaetano Di Chiara · 2016. 11. 7. · Wayne C. Drevets, M.D., Julie C. Price, Ph.D., David J. Kupfer, M.D., Paul E. Kinahan, P Brian
Page 26: Neurobiology of vulnerability to drug dependence. Gaetano Di Chiara · 2016. 11. 7. · Wayne C. Drevets, M.D., Julie C. Price, Ph.D., David J. Kupfer, M.D., Paul E. Kinahan, P Brian
Page 27: Neurobiology of vulnerability to drug dependence. Gaetano Di Chiara · 2016. 11. 7. · Wayne C. Drevets, M.D., Julie C. Price, Ph.D., David J. Kupfer, M.D., Paul E. Kinahan, P Brian

0 60 120 1800

100

200

300

400

Fischer (n=9)Lewis (n=6)

SHELL

0 60 120 1800

100

200

300

400

Fischer (n=5)Lewis (n=8)

SHELL

* *****

0 60 120 1800

100

200

300

400

Fischer (n=8)Lewis (n=8)

** *

SHELL

0 60 120 1800

100

200

300

400

Fischer (n=7)Lewis (n=8)

CORE

* * * ****

0 60 120 1800

100

200

300

400

Fischer (n=7)Lewis (n=11)

CORE

0 60 120 1800

100

200

300

400

Fischer (n=7)Lewis (n=7)

* *

CORE

1 mg/kg s.c. 5 mg/kg s.c.%

of b

asal

DA

outp

ut

time (min) after morphine

2.5 mg/kg s.c.

Morphine on dialysate dopamine in n.accumbens shell and core

Page 28: Neurobiology of vulnerability to drug dependence. Gaetano Di Chiara · 2016. 11. 7. · Wayne C. Drevets, M.D., Julie C. Price, Ph.D., David J. Kupfer, M.D., Paul E. Kinahan, P Brian

0 60 120 1800

100

200

300

400

500

600

700

Fischer (n=5)Lewis (n=6)

SHELL

* **

* *

0 60 120 1800

100

200

300

400

500

600

700

Fischer (n=9)Lewis (n=6)

SHELL

0 60 120 1800

100

200

300

400

500

600

700

Fischer (n=10)Lewis (n=5)

SHELL

0 60 120 1800

100

200

300

400

500

600

700

Fischer (n=6)Lewis (n=6)

CORE

* * * *****

0 60 120 1800

100

200

300

400

500

600

700

Fischer (n=8)Lewis (n=8)

************

**

CORE

0 60 120 1800

100

200

300

400

500

600

700

Fischer (n=6)Lewis (n=5)

CORE

****

**

% o

f bas

al D

A ou

tput

time (min) after amphetamine

0.25 mg/kg sc.c 0.5 mg/kg s.c. 1 mg/kg s.c.

Amphetamine on dialysate dopamine in n.accumbens shell and core

Page 29: Neurobiology of vulnerability to drug dependence. Gaetano Di Chiara · 2016. 11. 7. · Wayne C. Drevets, M.D., Julie C. Price, Ph.D., David J. Kupfer, M.D., Paul E. Kinahan, P Brian

0 60 120 1800

100

200

300

400

500

600

Fischer (n=7)Lewis (n=6)

SHELL

0 60 120 1800

100

200

300

400

500

600

Fischer (n=10)Lewis (n=8)

SHELL

0 60 120 1800

100

200

300

400

500

600

Fischer (n=6)Lewis (n=7)

SHELL

** ***

0 60 120 1800

100

200

300

400

500

600

Fischer (n=6)Lewis (n=10)

CORE

** ** *

0 60 120 1800

100

200

300

400

500

600

Fischer (n=6)Lewis (n=8)

**

CORE

0 60 120 1800

100

200

300

400

500

600

Fischer (n=7)Lewis (n=8)

CORE

5 mg/kg i.p. 10 mg/kg i.p. 20 mg/kg i.p.%

of b

asal

DA

outp

ut

time (min) after cocaine

Cocaine on dialysate dopamine in n.accumbens shell and core

Page 30: Neurobiology of vulnerability to drug dependence. Gaetano Di Chiara · 2016. 11. 7. · Wayne C. Drevets, M.D., Julie C. Price, Ph.D., David J. Kupfer, M.D., Paul E. Kinahan, P Brian

0 60 120 1800

100

200

300

Fischer (n=4)Lewis (n=6)

SHELL

0 60 120 1800

100

200

300

Fischer (n=4)Lewis (n=5)

SHELL

0 60 120 1800

100

200

300

Fischer (n=3)Lewis (n=6)

SHELL

* * ** *

0 60 120 1800

100

200

300

Fischer (n=6)Lewis (n=6)

SHELL

0 60 120 1800

100

200

300

Fischer (n=3)Lewis (n=5)

CORE

0 60 120 1800

100

200

300

Fischer (n=5)Lewis (n=5)

CORE

0 60 120 1800

100

200

300

Fischer (n=3)Lewis (n=4)

CORE

* *

0 60 120 1800

100

200

300

Fischer (n=3)Lewis (n=7)

* * *

CORE

time (min) after nicotine

% o

f bas

al D

A ou

tput

0.2 mg/kg s.c. 0.4 mg/kg s.c.0.1 mg/kg s.c.0.05 mg/kg s.c.

Nicotine on dialysate dopamine in n.accumbens shell and core

Page 31: Neurobiology of vulnerability to drug dependence. Gaetano Di Chiara · 2016. 11. 7. · Wayne C. Drevets, M.D., Julie C. Price, Ph.D., David J. Kupfer, M.D., Paul E. Kinahan, P Brian

concentric microdialysis probe

Page 32: Neurobiology of vulnerability to drug dependence. Gaetano Di Chiara · 2016. 11. 7. · Wayne C. Drevets, M.D., Julie C. Price, Ph.D., David J. Kupfer, M.D., Paul E. Kinahan, P Brian
Page 33: Neurobiology of vulnerability to drug dependence. Gaetano Di Chiara · 2016. 11. 7. · Wayne C. Drevets, M.D., Julie C. Price, Ph.D., David J. Kupfer, M.D., Paul E. Kinahan, P Brian
Page 34: Neurobiology of vulnerability to drug dependence. Gaetano Di Chiara · 2016. 11. 7. · Wayne C. Drevets, M.D., Julie C. Price, Ph.D., David J. Kupfer, M.D., Paul E. Kinahan, P Brian
Page 35: Neurobiology of vulnerability to drug dependence. Gaetano Di Chiara · 2016. 11. 7. · Wayne C. Drevets, M.D., Julie C. Price, Ph.D., David J. Kupfer, M.D., Paul E. Kinahan, P Brian

A.P. 1.7

A.P. 1.6

A.P. 1.2

SHELL CORE0

25

50

75

100

125

DA

BA

SAL

VALU

ES(fm

oles

/10

min

)

Location of microdialysis probes in rats responding for i.v. cocaine

Lecca et al

Page 36: Neurobiology of vulnerability to drug dependence. Gaetano Di Chiara · 2016. 11. 7. · Wayne C. Drevets, M.D., Julie C. Price, Ph.D., David J. Kupfer, M.D., Paul E. Kinahan, P Brian

0 5 10 15 20 25

0

10

20

30

40

50

60FR1 FR5

EXTINCTION

×

ACTIVEINACTIVE

FALSE ACTIVE

MASTER RATS YOKED RATS

FALSE INACTIVE

NO

SE-P

OK

ES

0 5 10 15 20 25

0.00

0.25

0.50

0

5

10

FR1 FR5

EXTINCTION

DAYSH

ER

OIN

IN

TA

KE

(mg/

kg)

INFU

SION

S(num

ber / 1 h)

*: p<0.05 vs. respective inactivex: p<0.05 vs. yoked false active nose-poke

Page 37: Neurobiology of vulnerability to drug dependence. Gaetano Di Chiara · 2016. 11. 7. · Wayne C. Drevets, M.D., Julie C. Price, Ph.D., David J. Kupfer, M.D., Paul E. Kinahan, P Brian

MASTER RATS(n= 5)

0 10 20 30 40 50 60 70 80 90

100

150

200

250

300shell 1st WEEKcore

DO

PAM

INE

OU

TPU

T(%

of b

asal

val

ues)

YOKED RATS(n=5)

0 10 20 30 40 50 60 70 80 90

100

150

200

250

300shell 1st WEEKcore

0 10 20 30 40 50 60 70 80 90

100

150

200

250

300shell 2nd WEEKcore

DO

PAM

INE

OU

TPU

T(%

of b

asal

val

ues)

0 10 20 30 40 50 60 70 80 9050

100

150

200

250

300shell 2nd WEEKcore

0 10 20 30 40 50 60 70 80 90

100

150

200

250

300shell 3rd WEEKcore

DO

PAM

INE

OU

TPU

T(%

of b

asal

val

ues)

0 10 20 30 40 50 60 70 80 90

100

150

200

250

300shell 3rd WEEKcore

0 10 20 30 40 50 60 70 80 90

100

150

200

250

300shell 4th WEEKcore

TIME (minutes)

DO

PAM

INE

OU

TPU

T(%

of b

asal

val

ues)

0 10 20 30 40 50 60 70 80 90

100

150

200

250

300shell 4th WEEKcore

TIME (minutes)

Filled symbols: p<0.05 vs basal values;*: p<0.05 vs core [master rats] or vs shell [yoked rats]x: p<0.05 vs yoked shell or vs master core

Page 38: Neurobiology of vulnerability to drug dependence. Gaetano Di Chiara · 2016. 11. 7. · Wayne C. Drevets, M.D., Julie C. Price, Ph.D., David J. Kupfer, M.D., Paul E. Kinahan, P Brian

MASTER RATS(n=5)

0 10 20 30 40 50 60 70 80 90

100

150

200

250

shellcore

TIME (minutes)

DO

PAM

INE

OU

TPU

T(%

of b

asal

val

ues)

YOKED RATS(n=5)

0 10 20 30 40 50 60 70 80 90

shellcore

TIME (minutes)

Filled symbols: p<0.05 vs basal values;*: p<0.05 vs core [master rats] or vs shell [yoked rats]x: p<0.05 vs yoked shell or vs master core

0.0

0.1

0.2

0.3

0.4

HERO

IN IN

TAKE

(mg/

kg)

Page 39: Neurobiology of vulnerability to drug dependence. Gaetano Di Chiara · 2016. 11. 7. · Wayne C. Drevets, M.D., Julie C. Price, Ph.D., David J. Kupfer, M.D., Paul E. Kinahan, P Brian

MASTER RATS:SHELL

0.0 0.2 0.4 0.6 0.8 1.0

0

500

1000

1500

2000

2500

slope= 1878±497

HEROIN INTAKE (mg/kg)

NET

DA

REL

EASE

(fmol

es/9

0 m

in)

MASTER RATS:CORE

0.0 0.2 0.4 0.6 0.8 1.0

0

500

1000

1500

2000

2500

slope= 656±205

HEROIN INTAKE (mg/kg)

YOKED RATS:SHELL

0.0 0.2 0.4 0.6 0.8 1.0

0

500

1000

1500

2000

2500

slope= 110±189

HEROIN INTAKE (mg/kg)

NET

DA

REL

EASE

(fmol

es/9

0 m

in)

YOKED RATS:CORE

0.0 0.2 0.4 0.6 0.8 1.0-500

0

500

1000

1500

2000

2500

slope= 1531±328

HEROIN INTAKE (mg/kg)

Page 40: Neurobiology of vulnerability to drug dependence. Gaetano Di Chiara · 2016. 11. 7. · Wayne C. Drevets, M.D., Julie C. Price, Ph.D., David J. Kupfer, M.D., Paul E. Kinahan, P Brian

0 10 20 30 40 50 60 70 80 90

100

150

200

250

300shell 5th WEEK: EXTINCTIONcore

TIME (minutes)

DO

PAM

INE

OUT

PUT

(% o

f bas

al v

alue

s)

0 10 20 30 40 50 60 70 80 90

shell 5th WEEK: EXTINCTIONcore

TIME (minutes)20

0

10

20

30

40

50

60

21 22 23 24 25

MASTER RATS YOKED RATSACTIVEINACTIVE FALSE ACTIVE

FALSE INACTIVE

×

DAYS

NO

SE-P

OK

ES

*: p<0.05 vs. respective inactivex: p<0.05 vs. yoked false active nose-poke

Page 41: Neurobiology of vulnerability to drug dependence. Gaetano Di Chiara · 2016. 11. 7. · Wayne C. Drevets, M.D., Julie C. Price, Ph.D., David J. Kupfer, M.D., Paul E. Kinahan, P Brian

Non-stereotyped activity• Still• Locomotion• Sniffing upward• Grooming• Rearing

Stereotyped activity• Gnawing (self-mutilation)• Gnawing confined• Sniffing down confined• Licking

Page 42: Neurobiology of vulnerability to drug dependence. Gaetano Di Chiara · 2016. 11. 7. · Wayne C. Drevets, M.D., Julie C. Price, Ph.D., David J. Kupfer, M.D., Paul E. Kinahan, P Brian

MASTER RATS

1 5 10 15 200

25

50

75

100

STEREOTYPED ACTIVITYNON-STEREOTYPED ACTIVITY

DAYS

% O

F TI

ME

SPEN

T *

** * ** * *

* * **

**

YOKED RATS

1 5 10 15 200

25

50

75

100

DAYS

* * ***

***

**

* *

*

* P < 0.05 VS. CORRESPONDING DAY-MATCHED COUNTERPART RATS ACTIVITY

Page 43: Neurobiology of vulnerability to drug dependence. Gaetano Di Chiara · 2016. 11. 7. · Wayne C. Drevets, M.D., Julie C. Price, Ph.D., David J. Kupfer, M.D., Paul E. Kinahan, P Brian

MASTER RATS

1 2 3 40

25

50

75

100

NON-STEREOTYPED ACTIVITY

STEREOTYPED ACTIVITY

WEEKS

% O

F TI

ME

SPEN

T *

**

YOKED RATS

1 2 3 40

25

50

75

100

*

WEEKS

*

*

* P < 0.05 VS. CORRESPONDING WEEK-MATCHED COUNTERPART RATS ACTIVITY

Page 44: Neurobiology of vulnerability to drug dependence. Gaetano Di Chiara · 2016. 11. 7. · Wayne C. Drevets, M.D., Julie C. Price, Ph.D., David J. Kupfer, M.D., Paul E. Kinahan, P Brian

MASTER RATSSHELL

0 10 20 30 40 50 60 70 80 900

200

400

600

800

1000D

A O

UTP

UT

(% o

f bas

al v

alue

s)

MASTER RATSCORE

0 10 20 30 40 50 60 70 80 900

200

400

600

800

1000

YOKED RATSSHELL

0 10 20 30 40 50 60 70 80 900

200

400

600

800

1000

TIME (minutes)

DA

OU

TPU

T(%

of b

asal

val

ues)

YOKED RATSCORE

0 10 20 30 40 50 60 70 80 900

200

400

600

800

1000

TIME (minutes)

DAY 1

DAY 2

DAY 3

DAY 4

DAY 5

DAY 6

DAY 7

DAY 8

DAY 9

DAY 10

DAY 11

DAY 12

DAY 13

DAY 14

DAY 15

Page 45: Neurobiology of vulnerability to drug dependence. Gaetano Di Chiara · 2016. 11. 7. · Wayne C. Drevets, M.D., Julie C. Price, Ph.D., David J. Kupfer, M.D., Paul E. Kinahan, P Brian

MASTER RATS

0 10 20 30 40 50 60 70 80 900

100

200

300

400

500 CORESHELL

TIME (minutes)

DO

PAM

INE

OU

TPU

T(%

of b

asal

val

ues)

YOKED RATS

0 10 20 30 40 50 60 70 80 90

CORESHELL

TIME (minutes)SHELL CORE

0.0

2.5

5.0

7.5

10.0

CO

CA

INE

INTA

KE

(mg/

kg)

Page 46: Neurobiology of vulnerability to drug dependence. Gaetano Di Chiara · 2016. 11. 7. · Wayne C. Drevets, M.D., Julie C. Price, Ph.D., David J. Kupfer, M.D., Paul E. Kinahan, P Brian

MASTER RATS:1ST WEEK

0 10 20 30 40 50 60 70 80 900

100

200

300

400

500CORESHELL

TIME (minutes)

DO

PAM

INE

OU

TPU

T(%

of b

asal

val

ues)

YOKED RATS:1ST WEEK

0 10 20 30 40 50 60 70 80 900

100

200

300

400

500CORESHELL

TIME (minutes)

SHELL CORE0.0

2.5

5.0

7.5

10.0

12.5

CO

CA

INE

INTA

KE

(mg/

kg)

MASTER RATS:2ND WEEK

0 10 20 30 40 50 60 70 80 900

100

200

300

400

500CORESHELL

TIME (minutes)

DO

PAM

INE

OU

TPU

T(%

of b

asal

val

ues)

YOKED RATS:2ND WEEK

0 10 20 30 40 50 60 70 80 900

100

200

300

400

500CORESHELL

TIME (minutes)

SHELL CORE0.0

2.5

5.0

7.5

10.0

12.5

CO

CA

INE

INTA

KE

(mg/

kg)

MASTER RATS:3RD WEEK

0 10 20 30 40 50 60 70 80 900

100

200

300

400

500CORESHELL

TIME (minutes)

DO

PAM

INE

OU

TPU

T(%

of b

asal

val

ues)

YOKED RATS:3RD WEEK

0 10 20 30 40 50 60 70 80 900

100

200

300

400

500CORESHELL

TIME (minutes)

SHELL CORE0.0

2.5

5.0

7.5

10.0

12.5

CO

CA

INE

INTA

KE

(mg/

kg)

Page 47: Neurobiology of vulnerability to drug dependence. Gaetano Di Chiara · 2016. 11. 7. · Wayne C. Drevets, M.D., Julie C. Price, Ph.D., David J. Kupfer, M.D., Paul E. Kinahan, P Brian

MASTER RATS:SHELL

0 10 20 30 40

0

1000

2000

3000

4000

5000

slope= 152.5±30.5

COCAINE INTAKE (mg/kg)

NET

DA

REL

EASE

(fmol

es/9

0 m

in)

MASTER RATS:CORE

0 10 20 30 40

slope= 89.7±24.4

COCAINE INTAKE (mg/kg)

YOKED RATS:SHELL

0 10 20 30 40

0

1000

2000

3000

4000

5000

slope= 37.8±8.6

COCAINE INTAKE (mg/kg)

NET

DA

REL

EASE

(fmol

es/9

0 m

in)

YOKED RATS:CORE

0 10 20 30 40

slope= 74.6±16.4

COCAINE INTAKE (mg/kg)

Page 48: Neurobiology of vulnerability to drug dependence. Gaetano Di Chiara · 2016. 11. 7. · Wayne C. Drevets, M.D., Julie C. Price, Ph.D., David J. Kupfer, M.D., Paul E. Kinahan, P Brian

Non-stereotyped activity• Still• Locomotion• Sniffing upward• Grooming• Rearing

Stereotyped activity• Sniffing down• Gnawing• Head bobbing• Licking

Page 49: Neurobiology of vulnerability to drug dependence. Gaetano Di Chiara · 2016. 11. 7. · Wayne C. Drevets, M.D., Julie C. Price, Ph.D., David J. Kupfer, M.D., Paul E. Kinahan, P Brian

MASTER RATS

1 2 3 4 5 6 7 8 9 10 11 12 13 14 150

25

50

75

100

STEREOTYPED ACTIVITYNON-STEREOTYPED ACTIVITY

* ***

** **

DAYS

% O

F TI

ME

SPEN

TYOKED RATS

1 2 3 4 5 6 7 8 9 10 11 12 13 14 150

25

50

75

100

* * **

* ** *

DAYS

* P < 0.05 VS. THE CORRESPONDING DAY-MATCHED COUNTERPART RATS ACTIVITY

Page 50: Neurobiology of vulnerability to drug dependence. Gaetano Di Chiara · 2016. 11. 7. · Wayne C. Drevets, M.D., Julie C. Price, Ph.D., David J. Kupfer, M.D., Paul E. Kinahan, P Brian
Page 51: Neurobiology of vulnerability to drug dependence. Gaetano Di Chiara · 2016. 11. 7. · Wayne C. Drevets, M.D., Julie C. Price, Ph.D., David J. Kupfer, M.D., Paul E. Kinahan, P Brian
Page 52: Neurobiology of vulnerability to drug dependence. Gaetano Di Chiara · 2016. 11. 7. · Wayne C. Drevets, M.D., Julie C. Price, Ph.D., David J. Kupfer, M.D., Paul E. Kinahan, P Brian